Kyowa Kirin Co., Ltd. $4151.T
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING3
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| KHK4951 NCT06116916 |
P2 | Active, not recruiting | Diabetic Macular Edema (DME) | 185 | 2026-10-31 (+12 mo) |
| ziftomenib NCT07623616 |
P2 | Recruiting | Acute Myeloid Leukemia (AML) | 6 | 2027-03 |
| KK2430 NCT07629726 |
P1/2 | Recruiting | Hematologic Neoplasms | 72 | 2027-04 |
| ME-401 NCT04533581 |
P2 | Active, not recruiting | Indolent B-cell Non-Hodgkin's Lymphoma | 61 | 2028-05-31 (+45 mo) |
| KK8398 NCT06926491 |
P3 | Active, not recruiting | Achondroplasia | 13 | 2029-05-31 |
| KK8123 NCT06525636 |
P1/2 | Recruiting | X-linked Hypophosphatemia | 39 | 2030-06-14 (+28 mo) |